Qarziba (Dinutuximab Beta) 20mg/4.5mL China | Anti-GD2 | GLT

REQUEST A QUOTE

Tap "Request a Quote" to open WhatsApp — the product details are already filled in. Just add your quantity and destination country.

  • We reply within 24 hours with pricing, availability & COA
  • Serves individuals and institutions worldwide

Prefer email? [email protected] · +86 15234153837

Share
Product description

Generic Information: Qarziba (China-Mainland)

Qarziba (凯泽百, dinutuximab beta) is the China-Mainland brand of dinutuximab beta, a chimeric mouse-human monoclonal antibody targeting the GD2 ganglioside. It is supplied as a 20 mg/4.5 mL concentrate for solution for infusion. Importantly, dinutuximab beta is a distinct product from dinutuximab: while both are anti-GD2 antibodies used against neuroblastoma, they are manufactured differently and marketed under separate brands. For Qarziba, the marketing authorisation holder (MAH) is Recordati Netherlands B.V. (the Netherlands), the manufacturer is Patheon Italia S.p.A. (Italy), and the product is marketed in China by BeiGene (Beijing) Co., Ltd. Qarziba was approved in China through a conditional approval pathway based on overseas clinical data.

What Is Dinutuximab Beta Used For?

Dinutuximab beta is used to treat high-risk neuroblastoma, a cancer of immature nerve cells that mainly affects young children. It is indicated for patients aged 12 months and older with high-risk neuroblastoma who have responded at least partially to induction chemotherapy and have completed myeloablative therapy and stem-cell transplantation. It is also used for relapsed or refractory neuroblastoma, with or without residual disease. Because treatment is intensive and given by intravenous infusion, it is administered in hospital under the supervision of an oncology team experienced in immunotherapy.

How Does Dinutuximab Beta Work?

Dinutuximab beta is a chimeric IgG1 monoclonal antibody that binds specifically to the GD2 ganglioside, a sugar-lipid antigen overexpressed on the surface of neuroblastoma cells. Once bound, the antibody triggers two immune-mediated mechanisms — complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) — that lead to the destruction of neuroblastoma cells. This redirects the patient's own immune system against the tumour. Because GD2 is also present on some normal nerve tissue, treatment requires careful premedication and pain management.

Indications

In China-Mainland, Qarziba (dinutuximab beta) is indicated for patients aged 12 months and older with high-risk neuroblastoma who have achieved at least a partial response to prior induction chemotherapy and have undergone myeloablative therapy followed by autologous stem-cell transplantation. It is also indicated for patients with relapsed or refractory neuroblastoma, with or without residual disease. Before treating relapsed disease, active progressive disease should be stabilised. The approval in China is a conditional approval based on overseas study data.

Dosage

Dinutuximab beta is given as an intravenous infusion in hospital. Each treatment cycle lasts 35 days with a total dose of 100 mg/m². This can be given either as a continuous 10-day infusion (10 mg/m² per day) or as five daily infusions (20 mg/m² per day, each over about 8 hours). Before each infusion, patients receive premedication with an antihistamine to reduce allergic reactions and analgesics (including non-opioid agents, gabapentin or morphine) to control the pain associated with anti-GD2 therapy. Administration must be supervised by specialists with resuscitation equipment immediately available.

Side Effects

The most common side effects of dinutuximab beta are fever (reported in about 88% of patients) and pain (about 77%), which requires preventive analgesia. Other frequent reactions include hypersensitivity reactions, vomiting, diarrhoea, capillary leak syndrome and low blood pressure. Cytokine release syndrome has been reported, and a small proportion of patients experience severe immediate allergic reactions. Pain usually occurs with the first infusion and diminishes over the course of treatment. Ocular effects, peripheral neuropathy and liver-enzyme changes can also occur and require monitoring by the treating team.

Storage

Qarziba should be stored at 2°C to 8°C, protected from light, and transported under cold-chain conditions. The concentrate must be prepared under sterile conditions and infused promptly after dilution. Prepared infusion solutions have limited storage times that must be respected. The medicine should be kept out of the reach of children and handled only by trained healthcare professionals.

Why Choose the China Version of Qarziba?

The China-Mainland Qarziba is the locally registered presentation of dinutuximab beta, with the marketing authorisation held by Recordati Netherlands B.V., manufacture by Patheon Italia S.p.A. and distribution in China through BeiGene. This documented chain — European MAH, Italian manufacturing and a leading Chinese oncology company handling commercialisation — gives hospitals and families a clearly traceable route to genuine product. Sourcing through GLT adds verification of authenticity, cold-chain integrity and the complete export documentation required for cross-border procurement of this specialised paediatric immunotherapy.

How to Order

To source China-Mainland Qarziba (dinutuximab beta) through GLT, contact us on WhatsApp at +86 15234153837 or email [email protected]. Tell us the quantity and your destination, and we will confirm current stock, cold-chain logistics and the import documentation required. This is a hospital-administered medicine, and we serve institutions as well as individual patients working with a treating oncology team.

FAQ

Is dinutuximab beta the same as dinutuximab? No. Dinutuximab beta (Qarziba) and dinutuximab (Unituxin) are both anti-GD2 antibodies for neuroblastoma, but they are distinct products with different manufacturing processes, marketing authorisation holders and brand names. This page describes dinutuximab beta.

Who holds the marketing authorisation for Qarziba? The marketing authorisation holder (MAH) is Recordati Netherlands B.V., the product is manufactured by Patheon Italia S.p.A. in Italy, and it is marketed in China by BeiGene (Beijing) Co., Ltd.

What is Qarziba used to treat? Qarziba (dinutuximab beta) treats high-risk neuroblastoma in patients aged 12 months and older, after induction chemotherapy and stem-cell transplantation, as well as relapsed or refractory neuroblastoma.

Is Qarziba covered by medical insurance in China? Dinutuximab beta is not listed in China's national medical insurance drug list, and it has been included in China's commercial health insurance innovative drug catalogue for neuroblastoma.

How is dinutuximab beta given? It is given by intravenous infusion in hospital, with each 35-day cycle delivering a total of 100 mg/m², either as a 10-day continuous infusion or five daily infusions.

Related Oncology Products

Rozlytrek (Entrectinib) 200mg Capsules | Hong Kong-Sourced NTRK/ROS1 Inhibitor | GLT

Roche (Hong Kong) original-brand entrectinib for ROS1-positive NSCLC and NTRK fusion-positive solid tumors — Hong...

Tafinlar (Dabrafenib) 50mg/75mg Capsules | BRAF Inhibitor | Novartis Turkey | GLT

Novartis's selective BRAF inhibitor for BRAF V600-mutated melanoma and NSCLC, supplied for Turkey.

Mekinib (Trametinib) 2mg*30's | Generic MEK Inhibitor | Sun Pharmaceutical Industries Ltd. | GLT

Generic trametinib (MEK inhibitor) by Sun Pharmaceutical Industries Ltd. (India) — an affordable alternative to...

LuciEntre (Entrectinib) Capsules | NTRK/ROS1 Inhibitor Generic | GLT

LuciEntre (Lucius Pharmaceuticals (Lao)) — entrectinib generic for ROS1-positive NSCLC and NTRK fusion-positive solid tumors.

Mekinist (Trametinib) 2mg Tablets | MEK Inhibitor | Novartis Switzerland | GLT

Novartis's first-in-class MEK inhibitor for BRAF-mutated melanoma and NSCLC, supplied for Switzerland.

PHOTRAME 2 (Trametinib) 2mg*30's | Generic MEK Inhibitor | Pharma 2 Vientiane | GLT

Generic trametinib (MEK inhibitor) by Pharma 2 Vientiane (Laos) — an affordable alternative to Mekinist...

Dabradx (Dabrafenib) 75mg | Generic BRAF Inhibitor | BigBear Pharmaceutical Co., Ltd. | GLT

Generic dabrafenib (BRAF inhibitor) by BigBear Pharmaceutical Co., Ltd. (Laos) — an affordable alternative to...

LuciPazo (Pazopanib) 200mg*120 | Lucius Laos Generic | GLT

Lucius Pharmaceuticals (Lao) — pazopanib 200mg generic for renal cell carcinoma & soft tissue sarcoma